ProCE Banner Activity

CME

The Evolution of Antibody–Drug Conjugates in Breast Cancer

Watch this on-demand Webcast capturing a live CCO Webinar with expert presentations on the evolving use of antibody–drug conjugates in the treatment of patients with advanced breast cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 30, 2020

Expiration: November 29, 2021

No longer available for credit.

Share

Faculty

Prof Michael Untch

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany

Javier Cortes

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Ian E. Krop

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Target Audience

This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the medical rationale and key advances in next-generation antibody–drug conjugates in breast cancer treatment
  • Integrate available and emerging HER2-directed antibody–drug conjugates for treatment of patients with HER2-positive breast cancer
  • Assess clinical trial results for newer antibody–drug conjugates in various breast cancer subsets

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany

Michael Untch, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Roche, and Samsung Bioepis.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD, has disclosed that he has received funds for research support (paid to his institution) from Ariad, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma, Roche, and Queen Mary University of London and consulting fees from AstraZeneca, Athenex, Bioasis, Biothera Pharmaceutical, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Erytech, GlaxoSmithKline, Leuko, Lilly, MedSIR, Merck Sharp & Dohme, Merus, Polyphor, Roche, Seattle Genetics, and Servier.

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ian Krop, MD, PhD, has disclosed that he has received funds for research support from Genentech and Pfizer and consulting fees from Context Therapeutics, Daiichi-Sankyo, Genentech, MacroGenics, Merck, Novartis, and Taiho Oncology.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 30, 2020, through November 29, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate new and emerging antibody–drug conjugate therapies into breast cancer treatment.